Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 26Small Cell Lung Carcinoma 22Neuroblastoma 12Fallopian Tube Neoplasms 12Uterine Cervical Neoplasms 8Carcinoma, Ovarian Epithelial 8Lung Neoplasms 7Neoplasm Metastasis 5Carcinoma, Non-Small-Cell Lung 4Leukemia, Myeloid, Acute 3Ganglioneuroblastoma 3Brain Neoplasms 3Sarcoma 2Recurrence 2Neuroectodermal Tumors, Primitive, Peripheral 2Neoplasms 2Hereditary Sensory and Autonomic Neuropathies 2Gliosarcoma 2Glioblastoma 2Central Nervous System Neoplasms 2Carcinoma, Small Cell 2Carcinoma, Neuroendocrine 2Thrombocythemia, Essential 1Sarcoma, Ewing 1Rhabdoid Tumor 1Retinoblastoma 1Retinal Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1

Interventions

Paclitaxel 2Letrozole 2trametinib 1ribociclib 1liposomal doxorubicin 1Topotecan 1Taxes 1Tamoxifen 1Doxorubicin 1Diphenhydramine 1Dexamethasone 1Cimetidine 1Axitinib 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Cystadenocarcinoma, Serous × Topotecan × Clear all
NCT02101788 2025-11-13

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

National Cancer Institute (NCI)

Phase 2/3 Completed
260 enrolled 20 charts

Cystadenocarcinoma, Serous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡